Catherine Smith

Catherine Smith

Auto-generated profile, based on publicly available information

Catherine Smith

Department of Infectious Diseases and the Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in EBioMedicine
Verified
Journal Article
Open access
CSCatherine D. Morffy Smith
Catherine D. Morffy Smith
MGMinghao Gong
Minghao Gong
AAAlicer K. Andrew
Alicer K. Andrew
BRBrittany N. Russ
Brittany N. Russ
YGYong Ge
Yong Ge
JMJulie Moore
Julie Moore
Malaria infection in pregnancy is a major cause of maternal and foetal morbidity and mortality worldwide. Mouse models for gestational malaria allow for the exploration of the mechanisms linking maternal malaria infection and poor pregnancy outcomes in a tractable model system. The composition of the gut microbiota has been shown to influence susceptibility to malaria infection in inbred virgin mice. In this study, we explore the ability of the gut microbiota to modulate malaria infection severity in pregnant outbred Swiss Webster mice. In Swiss Webster mice, the composition of the gut microbiota was altered by disrupting the native gut microbes through broad-spectrum antibiotic treatment, followed by the administration of a faecal microbiota transplant derived from mice possessing gut microbes reported previously to confer susceptibility or resistance to malaria. Female mice were infected with P. chabaudi chabaudi AS in early gestation, and the progression of infection and pregnancy were tracked throughout gestation. To assess the impact of maternal infection on foetal outcomes, dams were sacrificed at term to assess foetal size and viability. Alternatively, pups were delivered by caesarean section and fostered to assess neonatal survival and pre-weaning growth in the absence of maternal morbidity. A group of dams was also euthanized at mid-gestation to assess infection and pregnancy outcomes. Susceptibility to infection varied significantly as a function of source of transplanted gut microbes. Parasite burden was negatively correlated with the abundance of five specific OTUs, including Akkermansia muciniphila and OTUs classified as Allobaculum, Lactobacillus, and S24-7 species. Reduced parasite burden was associated with reduced maternal morbidity and improved pregnancy outcomes. Pups produced by dams with high parasite burdens displayed a significant reduction in survival in the first days of life relative to those from malaria-resistant dams when placed with foster dams. At midgestation, plasma cytokine levels were similar across all groups, but expression of IFNγ in the conceptus was elevated in infected dams, and IL-10 only in susceptible dams. In the latter, transcriptional and microscopic evidence of monocytic infiltration was observed with high density infection; likewise, accumulation of malaria haemozoin was enhanced in this group. These responses, combined with reduced vascularization of the placenta in this group, may contribute to poor pregnancy outcomes. Thus, high maternal parasite burden and associated maternal responses, potentially dictated by the gut microbial community, negatively impacts term foetal health and survival in the early postnatal period. The composition of the gut microbiota in Plasmodium chabaudi chabaudi AS-infected pregnant Swiss Webster mice transcends the outbred genetics of the Swiss Webster mouse stock as a determinant of malaria infection severity, subsequently influencing pregnancy outcomes in malaria-exposed progeny. FUND: Research reported in this manuscript was supported by the University of Florida College of Veterinary Medicine (JMM, MM, and MG), the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award numbers T32AI060546 (to CDMS), R01HD46860 and R21AI111242 (to JMM), and R01 DK109560 (to MM). MG was supported by Department of Infectious Diseases and Immunology and University of Florida graduate assistantships. AA was supported by the 2017-2019 Peach State LSAMP Bridge to the Doctorate Program at the University of Georgia (National Science Foundation, Award # 1702361). The content is solely the responsibility of the authors and does not necessarily represent official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, or the National Institutes of Health.

16 June 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
MLMarlise R. Luskin
Marlise R. Luskin
PGPhyllis A. Gimotty
Phyllis A. Gimotty
CSCatherine Smith
Catherine Smith
ALAlison W. Loren
Alison W. Loren
MFMaria E. Figueroa
Maria E. Figueroa
GWGerald B.W. Wertheim
Gerald B.W. Wertheim
BACKGROUND. Variable response to chemotherapy in acute myeloid leukemia (AML) represents a major treatment challenge. Clinical and genetic features incompletely predict outcome. The value of clinical epigenetic assays for risk classification has not been extensively explored. We assess the prognostic implications of a clinical assay for multilocus DNA methylation on adult patients with de novo AML. METHODS. We performed multilocus DNA methylation assessment using xMELP on samples and calculated a methylation statistic (M-score) for 166 patients from UPENN with de novo AML who received induction chemotherapy. The association of M-score with complete remission (CR) and overall survival (OS) was evaluated. The optimal M-score cut-point for identifying groups with differing survival was used to define a binary M-score classifier. This classifier was validated in an independent cohort of 383 patients from the Eastern Cooperative Oncology Group Trial 1900 (E1900; NCT00049517). RESULTS. A higher mean M-score was associated with death and failure to achieve CR. Multivariable analysis confirmed that a higher M-score was associated with death ( P = 0.011) and failure to achieve CR ( P = 0.034). Median survival was 26.6 months versus 10.6 months for low and high M-score groups. The ability of the M-score to perform as a classifier was confirmed in patients ≤ 60 years with intermediate cytogenetics and patients who achieved CR, as well as in the E1900 validation cohort. CONCLUSION. The M-score represents a valid binary prognostic classifier for patients with de novo AML. The xMELP assay and associated M-score can be used for prognosis and should be further investigated for clinical decision making in AML patients.

1 January 2015 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
GWGerald B W Wertheim
Gerald B W Wertheim
CSCatherine Smith
Catherine Smith
MLMarlise Luskin
Marlise Luskin
ARAlison Rager
Alison Rager
MFMaria E Figueroa
Maria E Figueroa
SMStephen R Master
Stephen R Master
BACKGROUND: Epigenetic dysregulation involving alterations in DNA methylation is a hallmark of various types of cancer, including acute myeloid leukemia (AML). Although specific cancer types and clinical aggressiveness of tumors can be determined by DNA methylation status, the assessment of DNA methylation at multiple loci is not routinely performed in the clinical laboratory.METHODS: We recently described a novel microsphere-based assay for multiplex evaluation of DNA methylation. In the current study, we validated and used an improved assay [termed expedited microsphere HpaII small fragment Enrichment by Ligation-mediated PCR (xMELP)] that can be performed with appropriate clinical turnaround time.RESULTS: Using the xMELP assay in conjunction with a new 17-locus random forest classifier that has been trained using 344 AML samples, we were able to segregate an independent cohort of 70 primary AML patients into methylation-determined subgroups with significantly distinct mortality risk (P = 0.009). We also evaluated precision, QC parameters, and preanalytic variables of the xMELP assay and determined the sensitivity of the random forest classifier score to failure at 1 or more loci.CONCLUSIONS: Our results demonstrate that xMELP performance is suitable for implementation in the clinical laboratory and predicts AML outcome in an independent patient cohort.

2 November 2016 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
CDCourtney D. Dinardo
Courtney D. Dinardo
MLMarlise R. Luskin
Marlise R. Luskin
MCMartin Carroll
Martin Carroll
CSCatherine Smith
Catherine Smith
JHJenna Harrison
Jenna Harrison
SMStephen R. Master
Stephen R. Master
Click on the article title to read more.

26 December 2013 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
PDF file
GWGerald B.W. Wertheim
Gerald B.W. Wertheim
CSCatherine Smith
Catherine Smith
MFMaria E. Figueroa
Maria E. Figueroa
MKMichael Kalos
Michael Kalos
ABAdam Bagg
Adam Bagg
SMStephen R. Master
Stephen R. Master
Cancer has been traditionally considered a genetic disease, involving a series of mutations that activate oncogenes and inactivate tumor suppressors.1 x 1 Hanahan, D. and Weinberg, R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674 Abstract | Full Text | Full Text PDF | PubMed | Scopus (23011) | Google Scholar See all References Although mutagenic events are critical for carcinogenesis, recent work has unequivocally demonstrated that cancer is also characterized by dysregulation of chromatin structure that involves the DNA itself (eg, CpG methylation) and its associated histones.2 x 2 Baylin, S.B. and Jones, P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11: 726–734 Crossref | PubMed | Scopus (1404) | Google Scholar See all References Because these epigenetic modifications are at least partially responsible for influencing tumorigenic processes, it is not surprising that several studies have demonstrated that prognosis of certain tumors can be predicted from analysis of epigenetic features.3 x 3 Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., Greally, J.M., Valk, P.J., Lowenberg, B., Delwel, R., and Melnick, A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17: 13–27 Abstract | Full Text | Full Text PDF | PubMed | Scopus (498) | Google Scholar See all References , 4 x 4 Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., Verhaak, R.G., Hoadley, K.A., Hayes, D.N., Perou, C.M., Schmidt, H.K., Ding, L., Wilson, R.K., Van Den Berg, D., Shen, H., Bengtsson, H., Neuvial, P., Cope, L.M., Buckley, J., Herman, J.G., Baylin, S.B., Laird, P.W., Aldape, K., and Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17: 510–522 Abstract | Full Text | Full Text PDF | PubMed | Scopus (1290) | Google Scholar See all References , 5 x 5 Portela, A. and Esteller, M. Epigenetic modifications and human disease. Nat Biotechnol. 2010; 28: 1057–1068 Crossref | PubMed | Scopus (1284) | Google Scholar See all References